AR085171A1 - Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contiene - Google Patents

Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contiene

Info

Publication number: AR085171A1
Authority: AR; Argentina
Prior art keywords: water; salt; crystalline; ralfinamide; impurities
Prior art date: 2010-04-27

Application number

ARP110101401A

Other languages

English (en)

Spanish (es)

Inventor

Giordano Claudio

Waldvogel Erwin

Original Assignee

Newron Pharm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-27

Filing date

2011-04-25

Publication date

2013-09-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42634917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR085171(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-04-25 Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa

2013-09-18 Publication of AR085171A1 publication Critical patent/AR085171A1/es

Links

BHJIBOFHEFDSAU-LBPRGKRZSA-N ralfinamide Chemical class C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1F BHJIBOFHEFDSAU-LBPRGKRZSA-N 0.000 title abstract 10
231100000024 genotoxic Toxicity 0.000 title abstract 7
230000001738 genotoxic effect Effects 0.000 title abstract 7
239000012535 impurity Substances 0.000 title abstract 7
238000004519 manufacturing process Methods 0.000 title abstract 4
238000000034 method Methods 0.000 title abstract 4
239000008194 pharmaceutical composition Substances 0.000 title 1
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 13
239000000203 mixture Substances 0.000 abstract 10
150000003839 salts Chemical class 0.000 abstract 10
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 7
125000004432 carbon atom Chemical group C* 0.000 abstract 7
RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 abstract 7
239000002243 precursor Substances 0.000 abstract 6
239000013557 residual solvent Substances 0.000 abstract 6
238000000634 powder X-ray diffraction Methods 0.000 abstract 5
239000007787 solid Substances 0.000 abstract 5
239000013078 crystal Substances 0.000 abstract 3
238000002425 crystallisation Methods 0.000 abstract 3
230000008025 crystallization Effects 0.000 abstract 3
239000002253 acid Substances 0.000 abstract 2
150000007513 acids Chemical class 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 abstract 2
150000002148 esters Chemical class 0.000 abstract 2
230000001747 exhibiting effect Effects 0.000 abstract 2
229940098779 methanesulfonic acid Drugs 0.000 abstract 2
238000000746 purification Methods 0.000 abstract 2
239000002002 slurry Substances 0.000 abstract 2
239000002904 solvent Substances 0.000 abstract 2
239000000126 substance Substances 0.000 abstract 2
-1 that is Chemical compound 0.000 abstract 2
238000004482 13C cross polarization magic angle spinning Methods 0.000 abstract 1
238000005481 NMR spectroscopy Methods 0.000 abstract 1
238000004458 analytical method Methods 0.000 abstract 1
238000012926 crystallographic analysis Methods 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
238000010438 heat treatment Methods 0.000 abstract 1
239000007909 solid dosage form Substances 0.000 abstract 1
230000004580 weight loss Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ARP110101401A 2010-04-27 2011-04-25 Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contiene AR085171A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP10161207		2010-04-27

Publications (1)

Publication Number	Publication Date
AR085171A1 true AR085171A1 (es)	2013-09-18

Family

ID=42634917

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ARP110101401A AR085171A1 (es)	2010-04-27	2011-04-25	Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contiene

Country Status (27)

Country	Link
US (2)	US9505708B2 (2)
EP (1)	EP2563355B1 (2)
JP (3)	JP5808392B2 (2)
KR (1)	KR101851118B1 (2)
CN (2)	CN102858330B (2)
AR (1)	AR085171A1 (2)
AU (1)	AU2011246707B2 (2)
BR (1)	BR112012027623B1 (2)
CA (1)	CA2794389C (2)
CY (1)	CY1117879T1 (2)
DK (1)	DK2563355T3 (2)
EA (1)	EA021389B1 (2)
ES (1)	ES2590128T3 (2)
HR (1)	HRP20161077T1 (2)
HU (1)	HUE030504T2 (2)
IL (1)	IL222532A (2)
LT (1)	LT2563355T (2)
ME (1)	ME02509B (2)
MX (1)	MX342697B (2)
NZ (2)	NZ700221A (2)
PL (1)	PL2563355T3 (2)
PT (1)	PT2563355T (2)
RS (1)	RS55084B1 (2)
SI (1)	SI2563355T1 (2)
SM (1)	SMT201600266B (2)
TW (1)	TWI492919B (2)
WO (1)	WO2011134763A1 (2)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2563355T1 (sl) *	2010-04-27	2016-10-28	Newron Pharmaceuticals S.P.A.	Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov
CN103804341B (zh) *	2012-11-13	2018-04-10	中国人民解放军军事医学科学院毒物药物研究所	酰胺衍生物及其医药用途
CN104761531B (zh) *	2014-01-03	2017-12-01	中国人民解放军军事医学科学院毒物药物研究所	镇痛活性化合物及其医药用途
CN104292128A (zh) *	2014-07-01	2015-01-21	南京正科制药有限公司	一种沙芬酰胺晶型a
CN115368310B (zh) *	2021-05-18	2025-06-27	奥库菲尔医药公司	合成甲磺酸酚妥拉明的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL94466A (en)	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9515412D0 (en) *	1995-07-27	1995-09-27	Pharmacia Spa	2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
DK1423168T3 (da)	2001-09-03	2006-05-15	Newron Pharm Spa	Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
EP1438956A1 (en) *	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful as antimigraine agents
WO2004066987A2 (en) *	2003-01-30	2004-08-12	Dynogen Pharmaceuticals, Inc.	Use of sodium channel modulators for treating gastrointestinal tract disorders
AR044007A1 (es)	2003-04-11	2005-08-24	Newron Pharmaceuticals Inc	Metodos para el tratamiento de la enfermedad de parkinson
DK1658062T3 (da)	2003-08-25	2010-05-31	Newron Pharm Spa	Alfa-aminoamid-derivater anvendelige som anti-inflammatoriske midler
EP1557166A1 (en)	2004-01-21	2005-07-27	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en)	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
DK1809271T5 (da) *	2004-09-10	2010-12-06	Newron Pharm Spa	Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
EP1870097A1 (en)	2006-06-15	2007-12-26	Newron Pharmaceuticals S.p.A.	Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
HUE030233T2 (en) *	2006-06-19	2017-04-28	Newron Pharm Spa	High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
JP5315674B2 (ja) *	2007-11-19	2013-10-16	セントラル硝子株式会社	非水電池用電解液及びこれを用いた非水電池
US8530701B2 (en) *	2007-12-11	2013-09-10	Newron Pharmaceuticals, S.P.A.	High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof
NZ586182A (en)	2007-12-19	2012-02-24	Newron Pharm Spa	Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
WO2009109334A1 (en)	2008-03-07	2009-09-11	Newron Pharmaceuticals S.P.A.	(s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
SI2563355T1 (sl) *	2010-04-27	2016-10-28	Newron Pharmaceuticals S.P.A.	Postopek za izdelavo metansulfonatnih soli ralfinamida ali njihovih R-enantiomerov

2011
- 2011-04-06 SI SI201130927A patent/SI2563355T1/sl unknown
- 2011-04-06 ES ES11714958.3T patent/ES2590128T3/es active Active
- 2011-04-06 HR HRP20161077TT patent/HRP20161077T1/hr unknown
- 2011-04-06 LT LTEP11714958.3T patent/LT2563355T/lt unknown
- 2011-04-06 BR BR112012027623-9A patent/BR112012027623B1/pt active IP Right Grant
- 2011-04-06 EP EP11714958.3A patent/EP2563355B1/en active Active
- 2011-04-06 PT PT117149583T patent/PT2563355T/pt unknown
- 2011-04-06 NZ NZ700221A patent/NZ700221A/en unknown
- 2011-04-06 HU HUE11714958A patent/HUE030504T2/en unknown
- 2011-04-06 NZ NZ602648A patent/NZ602648A/en unknown
- 2011-04-06 CA CA2794389A patent/CA2794389C/en active Active
- 2011-04-06 RS RS20160665A patent/RS55084B1/sr unknown
- 2011-04-06 CN CN201180020748.2A patent/CN102858330B/zh active Active
- 2011-04-06 ME MEP-2016-169A patent/ME02509B/me unknown
- 2011-04-06 EA EA201291116A patent/EA021389B1/ru unknown
- 2011-04-06 AU AU2011246707A patent/AU2011246707B2/en active Active
- 2011-04-06 JP JP2013506566A patent/JP5808392B2/ja active Active
- 2011-04-06 DK DK11714958.3T patent/DK2563355T3/en active
- 2011-04-06 KR KR1020127030931A patent/KR101851118B1/ko active Active
- 2011-04-06 US US13/643,716 patent/US9505708B2/en active Active
- 2011-04-06 WO PCT/EP2011/055309 patent/WO2011134763A1/en not_active Ceased
- 2011-04-06 MX MX2012012093A patent/MX342697B/es active IP Right Grant
- 2011-04-06 PL PL11714958.3T patent/PL2563355T3/pl unknown
- 2011-04-06 CN CN201510387405.XA patent/CN105037188B/zh active Active
- 2011-04-18 TW TW100113339A patent/TWI492919B/zh active
- 2011-04-25 AR ARP110101401A patent/AR085171A1/es not_active Application Discontinuation
2012
- 2012-10-18 IL IL222532A patent/IL222532A/en active IP Right Grant
2015
- 2015-05-22 JP JP2015104930A patent/JP6345154B2/ja active Active
2016
- 2016-08-05 SM SM201600266T patent/SMT201600266B/it unknown
- 2016-08-10 CY CY20161100786T patent/CY1117879T1/el unknown
- 2016-10-12 US US15/291,202 patent/US9856207B2/en active Active
2017
- 2017-05-30 JP JP2017106571A patent/JP6450420B2/ja active Active

Also Published As

Publication number	Publication date
HUE030504T2 (en)	2017-05-29
CN105037188A (zh)	2015-11-11
LT2563355T (lt)	2016-09-26
JP6345154B2 (ja)	2018-06-20
JP6450420B2 (ja)	2019-01-09
BR112012027623B1 (pt)	2021-07-06
US20130039983A1 (en)	2013-02-14
EA201291116A1 (ru)	2013-04-30
SI2563355T1 (sl)	2016-10-28
WO2011134763A1 (en)	2011-11-03
CY1117879T1 (el)	2017-05-17
JP5808392B2 (ja)	2015-11-10
MX2012012093A (es)	2012-12-17
EP2563355A1 (en)	2013-03-06
ES2590128T3 (es)	2016-11-18
NZ602648A (en)	2014-10-31
HK1179881A1 (en)	2013-10-11
NZ700221A (en)	2016-04-29
HRP20161077T1 (hr)	2016-10-21
KR20130094212A (ko)	2013-08-23
JP2013528577A (ja)	2013-07-11
IL222532A0 (en)	2012-12-31
RS55084B1 (sr)	2016-12-30
MX342697B (es)	2016-10-10
CN102858330B (zh)	2015-07-22
EA021389B1 (ru)	2015-06-30
US9856207B2 (en)	2018-01-02
SMT201600266B (it)	2016-08-31
TW201139344A (en)	2011-11-16
AU2011246707B2 (en)	2014-11-20
IL222532A (en)	2017-09-28
US9505708B2 (en)	2016-11-29
EP2563355B1 (en)	2016-06-08
HK1213872A1 (zh)	2016-07-15
CA2794389C (en)	2016-08-23
US20170029365A1 (en)	2017-02-02
CN102858330A (zh)	2013-01-02
ME02509B (me)	2017-02-20
JP2017197553A (ja)	2017-11-02
DK2563355T3 (en)	2016-09-12
CN105037188B (zh)	2017-06-23
JP2015180664A (ja)	2015-10-15
PT2563355T (pt)	2016-09-02
TWI492919B (zh)	2015-07-21
BR112012027623A2 (pt)	2016-08-09
CA2794389A1 (en)	2011-11-03
KR101851118B1 (ko)	2018-04-23
PL2563355T3 (pl)	2016-12-30

Legal Events

Date	Code	Title	Description
2023-03-30	FC	Refusal

Publication	Publication Date	Title
ES2656239T3 (es)	2018-02-26	Método de preparación de la forma cristalina I del racemato de 4-hidroxido-2-oxo-1-pirrolidina-acetamida
RU2663663C2 (ru)	2018-08-08	Соль омекамтива мекарбила и способ ее получения
CU20120072A7 (es)	2012-10-15	Proceso para la preparación del calcobutrol
AR085171A1 (es)	2013-09-18	Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contiene
AR080819A1 (es)	2012-05-09	Sintesis estereoselectiva de activos que contienen fosforo
RU2627698C2 (ru)	2017-08-10	Натриевая соль (2s, 5r)-6-бензилокси-7-оксо-1,6-диаза-бицикло[3.2.1]октан-2-карбоновой кислоты и ее получение
US11352323B2 (en)	2022-06-07	Processes for making, and methods of using, glycopyrronium compounds
ES2745157T3 (es)	2020-02-27	Un método para la preparación, aislamiento y purificación de formas farmacéuticamente aplicables de AHU-377
CN104610360A (zh)	2015-05-13	一种富马酸替诺福韦二吡呋酯的制备方法
ITMI20101239A1 (it)	2012-01-07	Processo ed intermedi per la preparazione di un principio attivo
CN108947989B (zh)	2021-07-02	氘代光学异构体及其医药用途
PT2532651E (pt)	2015-10-15	Processo de síntese e forma cristalina docloridrato de 4-{3-[cishexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida bem como da base livre associada e das composições farmacêuticas que os contenham
CN107090000A (zh)	2017-08-25	一种苯并硼唑7位脂肪酸的衍生物及其制备与药物用途
Hu et al.	2015	Resolutions of sibutramine with enantiopure tartaric acid derivatives: chiral discrimination mechanism
TW202024035A (zh)	2020-07-01	用於製備(-)-琥珀酸西苯唑啉的新穎方法
CN104130146A (zh)	2014-11-05	(4s)-3,6,9-三氮杂-3,6,9-三(羧甲基)-4-(4-乙氧基苄基)十一烷二酸的制备方法
ES2668771T3 (es)	2018-05-22	Métodos para la producción de L-carnitina
CA3170252A1 (en)	2021-09-10	Pyrimidine compounds and their pharmaceutical uses
FR2892721B1 (fr)	2009-07-24	Nouveau procede de preparation de sels d'acides et d'ammonium quaternaires
CN103012281B (zh)	2015-04-08	一种手性2-[(4,6-二甲基嘧啶-2-基)氧基]-3-甲氧基-3,3-二苯基丙酸的消旋化方法
CA3030772C (en)	2025-09-16	Processes for making, and methods of using, glycopyrronium compounds
CN104693071A (zh)	2015-06-10	一种n- 羟基-n’- 苯基辛二酰胺制备方法
JP2012240959A (ja)	2012-12-10	光学活性β−アミノチオールまたは光学活性β−アミノスルホン酸誘導体の合成法
ES2669750T3 (es)	2018-05-29	Un proceso para producir saxagliptina
CA3191657A1 (en)	2022-03-10	Stat inhibitory compounds and compositions